Barry Vucsko
SVP, Client Partner, Account Services
Expertise:
Barry Vucsko has more than 25 years of marketing, advertising, and consulting experience spanning more than 100 brands and several continents. His pharma advertising career has spanned creative, strategy and account leadership. Barry has extensive experience with HCP, Consumer and Managed Care targets, as well as Global and US launches for everything from oncology to ultra-rare and blockbuster treatments. He has a proven track record of developing integrated brand communications that achieve impact and drive business. Barry has an MBA from Indiana University’s Kelley School of Business and a BA from Columbia College Chicago.
Articles by Barry Vucsko
Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024
Every year, the European Society for Medical Oncology (ESMO) brings together experts from pharma, research and advocacy organizations, and healthcare providers (HCPs) to hear about the year’s biggest oncology breakthroughs. With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. EVERSANA was there with teams from across the U.S. and EU. Here are a few of the things we learned and some associated implications heading into 2025. Artificial intelligence in oncology: AI was finally featured at a major oncology conference, with presentations including presidential symposia and conference booths establishing its place in the […]
The Necessity of Mapping the Tumor Journey for Oncology Marketers
EVERSANA INTOUCH has been pioneering a Tumor Journey that considers the complex, multi-factorial decision making that permeates every stage of oncologic patient care. Oncology Marketing has been slow in evolving to consider the complexities of diagnosis, treatment, and overall patient care decisions made by multiple stakeholders. We continue to rely on traditional patient journeys and marketing-orientated journeys that solely aim to map the patient or HCP experience. With the increasing number of technological advances and personalized therapies driven by new discoveries in tumor biology, treatment teams are simultaneously becoming more specialized in focus and more diverse in their composition. Our marketing efforts must adapt to this changing landscape by mapping […]